Выпуск
Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab
Pharmaceutical Executive · 7 октября 2026 г. · 2 мин
Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a first-line maintenance therapy in HER2-positive breast cancer.